According to the results of the survey, 64% of respondents reported waiting at least one business day for a PA decision from health plans, with 30% waiting at least three business days.
The researchers found that during the 3-year study period, about 98 million outpatient antibiotic prescriptions were filled by 39 million insurance beneficiaries. Azithromycin, amoxicillin, amoxicillin/clavulanate, ciprofloxacin, and cephalexin were the most commonly prescribed antibiotics.
One major reason reported for the lack of use was a perceived increase in workload (51%). Most respondents reported a positive perception of this model and interactions with pharmacists, and were also confident in their ability to safely recommend medication (63%).
Experts say strategies can be employed to help reduce stress while at the pharmacy; these include pharmacists taking a few minutes each day to talk to customers and refocus on why they chose this profession, as well as taking time for reflection before work or after the shift.
Use of the technology at the Summa Health System-Barberton Campus in Ohio has been beneficial, saving time for pharmacists and technicians even though the amount of time savings has not been fully realized as use of the technology is in early phases.
The Pharmacy Technician Forum will provide necessary education, tools, and resources needed to advance the career paths of technicians and enhance their roles as members of the interprofessional patient care team.
Specifically, the organizations provide a call to action for Congress to determine how manufacturers should handle disclosing drug shortages to the medical community.
Reporting on a study of the reaction of children to morphine administration at SLEEP 2015, Gaspard Montandon, PhD, University of Toronto, said that respiratory depression was "more severe when patients were in states of reduced arousal due to the sedative properties of morphine."
Severe obstructive sleep apnea syndrome (OSAS) may potentially be associated with pancreatic β-cell functional disorder and glucagon-like peptide-1 (GLP-1) resistance, according to a study presented at SLEEP 2015.
Chewing caffeine gum for five minutes immediately upon awakening may counter sleep inertia, especially for reaction time, according to a data presented at SLEEP 2015.
Administration of a non-benzodiazepine sedative hypnotic (NBSH) does not increase the likelihood of having a low arousal phenotype for obstructive sleep apnea (OSA), a study presented at SLEEP 2015 has concluded.
The orexin receptor antagonist suvorexant improves sleep in patients with insomnia, analysis of pooled results of two Phase 3 clinical trials presented at SLEEP 2015 have found.
Lemborexant (E2006), a dual orexin receptor antagonist (DORA) under development for insomnia disorder, led to a decrease in latency to persistent sleep (LPS) and wake after sleep onset (WASO) and an increase in sleep efficiency (SE), according to data presented at SLEEP 2015.
Sodium oxybate improved health-related quality-of-life (HRQoL) measures in patients with narcolepsy in a dose-dependent manner, results from a randomized placebo-controlled trial presented at SLEEP 2015 have found.
Pharmacotherapy improves multiple domains of functioning in patients with central disorders of hypersomnolence (CDH) in a "real-world" tertiary care setting, according to data presented at SLEEP 2015.
A case study presented at SLEEP 2015 suggest that an influenza vaccination may have triggered status cataplecticus in the female patient with known narcolepsy.
Milnacipran does not directly improve sleep continuity and architecture but its impact on sleep improvement can be attributed to its effectiveness in reducing pain, according to data presented at SLEEP 2015.
When eszopiclone was given instead of zolpidem, no difference was observed on the polysomnogram diagnostic and positive airway pressure (PAP)-titration portions, according to data reported at SLEEP 2015.
An 80-year-old male with new onset myasthenia gravis and narcolepsy with cataplexy had symptomatic improvement with sodium oxybate—but not with immune-modulating agents, results of a case study presented at SLEEP 2015 have shown.
E2006, a novel dual orexin receptor antagonist (DORA), has shown efficacy for both subject-reported sleep onset and maintenance on sleep diary measures, according to Phase 2 study results reported at SLEEP 2015.
Almorexant, a hypocretin receptor antagonist, produced fewer acute cognitive effects than the GABAA receptor modulator zolpidem, according to results of a randomized controlled trial presented at SLEEP 2015.
Treatment with gabapentin enacarbil at both the 600mg and 1200mg doses "led to a greater number of adult patients who met the criteria for a combined pain and International Restless Legs Scale (IRLS) total score response" compared to placebo, a study presented at SLEEP 2015 confirmed.
For about one-third of patients treated with zolpidem, only partial improvement is observed, researchers reported at SLEEP 2015.
Higher levels of vitamin E improve spatial memory performance in sleep-deprived women, according to data presented at SLEEP 2015.
Suvorexant (Belsomra; Merck) 20mg/15mg and 40mg/30mg tablets were generally effective and well tolerated by both women and men with insomnia, according to a subgroup analysis of Phase 3 data presented at SLEEP 2015.
Clinician- and patient-reported assessments of global impression of change in disease status had "good concordance" for narcolepsy treated with JZP-110, a novel wake-promoting agent, according to results of a post hoc analysis reported at SLEEP 2015.
In patients with treatment-resistant nocturnal frontal lobe epilepsy (NFLE), lacosamide may be an effective option, researchers concluded at SLEEP 2015.
Further clinical investigation of the selective high affinity/potent dual orexin-2 receptor antagonist (OX2R) JNJ-42847922 is supported by preclinical and Phase 1 clinical data, a characterization of the agent presented at SLEEP 2015 has found.